Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Oratie Michiel van de Sande over vooruitgang sarcoomzorg
nov 2021 | Bot en wekedelentumoren